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Summary
Purpose: To further evaluate the safety, efficacy and optimal dose of levetiracetam
(LEV) in daily clinical practice among patients with uncontrolled partial epilepsy with
or without secondary generalization.
Methods: In this phase IV, open-label, 16-week community-based study, 178 at least
16-year-old patients with refractory focal epilepsy were treated with 1000, 2000 or
3000 mg levetiracetam as adjunctive therapy. All patients started with 500 mg LEV
b.i.d. (1000 mg/day); the dose was adjusted in 2-week intervals up to 1500 b.i.d.
(3000 mg/day) depending on seizure control and tolerability. The main objectives
were the adverse events, the percentage reduction in partial and total seizure
frequency per week from baseline and the retention rate, defined as the percentage
of patients taking LEV at the end of the 16-week treatment period.
Results: Of the 178 patients who took at least one dose of LEV 151 completed the
study. Thus, the retention rate (number of patients taking LEV at the end of the 16-
week treatment period) was 84.8%. Most frequently reported adverse events were
asthenia, dizziness, headache, nausea, somnolence and hostility; the majority of
these events were of mild to moderate intensity. The seizure-free rate of the ITT
population with focal seizures was 16.7%, for all seizures 16.6%; the median reduction
of focal seizure frequency was 47.6%, and 46.5% for all seizures. The 50% responder
rate was 46.6% for focal seizures and 45.1% for all seizures.
Conclusion: Add-on treatment with LEV in patients with refractory partial epilepsy
was safe and effective in this study.
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Levetiracetam (LEV, Keppra1) has been approved
since the year 2000 as an add-on treatment for adult
patients with focal seizures with or without second-
ary generalization. The results of the placebo-con-
trolled studies leading to approval and the open-
label extension studies indicate that LEV constitutes
a considerable progress in the treatment of epi-
lepsy.2,3,14 Only half of patients achieve adequate
seizure control following monotherapy with the
initial antiepileptic drug (AED)8 which requires
add-on therapy with a second or even third agent.
In placebo-controlled trials investigating this add-on
treatment, responder rates with LEV were signifi-
cantly higher compared to placebo. The occurrence
of adverse events was comparable for LEV and
placebo; slightly more frequent in the LEV group
were asthenia, somnolence and headache.
Inaddition to theadvantageousefficacyand safety
properties, LEV has an almost perfect pharmacoki-
netic profile12,13: about 100% bioavailability, less
than 48 h to steady state, linear kinetics, twice-daily
dosing, protein binding less than 10%, no hepatic
metabolism, minimal metabolism in blood, no sig-
nificant interactions with other AEDs. Recently, the
binding site of LEV was discovered9: the synaptic
vesicle protein SV2A is the brain-binding site of
LEV. Probably, LEV acts by modulating the function
of SV2A, supporting previous indications that LEV
possesses a mechanism of action that is different
from other AEDs. There are reports of other effects
of LEV, including the partial inhibition of N-type high-
voltage-gated Ca2+ channels and the reduction of
inhibition of GABA and glycine-gated currents.10
Furthermore, LEV has been shown to delay the devel-
opment of kindling, indicating that it may have dis-
ease-modifying properties to the development that
results in reduced seizure threshold.7
The SKATE study (Safety of Keppra1 as Adjunctive
Therapy in Epilepsy) was conducted to evaluate the
safety and efficacy of LEV in a population that repre-
sents the patients seen by physicians in their daily
clinical practice. In general, 50% of epilepsy patients
become seizure-free with the first monotherapy,
further 25% become seizure-free with an alternative
mono- or combination therapy, whereas 25% are
refractory to any drug treatment. In the phase III
studies, which led to LEV approval, the participants
were chosen from the 25% of patients whose seizures
are refractory to any treatment. In the SKATE study,
patients were recruited whose seizures could not be
sufficiently controlled with one or two AEDs thus
reflecting a very similar population. This report dis-
plays the result of the pooled data of the Austrian,
German and Swiss part of the SKATE study, in order toprovide useful information to clinicians on the opti-
mal use of LEV as add-on treatment in a relevant
number of patients with epilepsy.Materials and methods
The SKATE study is a 16-week, phase IV,multi-centre,
open-label, community-based trial of LEV as add-on
therapy in patients with uncontrolled focal seizures.
The study is conducted in accordance with ICH-GCP
guidelines, the Declaration of Helsinki, and the
national laws of the countries involved. This article
reports the study results of the patients recruited for
theSKATE study inAustria,GermanyandSwitzerland.
Patients
At least 16-year-old men and women experiencing
focal epileptic seizures with or without secondary
generalization that were classifiable according to
the International Classification of Epileptic Sei-
zures4 could be enrolled. Eligible patients had at
least 1 but not more than 14 focal seizures per
month in the 3-month baseline period, resulting in
3—42 seizures in the period preceding study entry.
The patients had been receiving one or two mar-
keted AEDs at a stable dosage for at least 4 weeks
before study entry; benzodiazepines used on a daily
basis were considered as one of the concomitant
AEDs, regardless of the prescribed indication.
Previous treatment with LEV, felbamate within 18
months prior to the study, vigabatrin treatment at
visit 1 and participation in another clinical study
within 12 weeks prior to the screening visit were
not permitted. Other exclusion criteria were ques-
tionable compliance, serious psychiatric disorders
within the previous 5 years, any condition that may
influence the pharmacokinetics of medication
(patients with mild to moderate renal impairment
were eligible), progressive cerebral or degenerative
neurological disease, cerebral tumors, terminal ill-
ness or anymedical condition thatmay interferewith
the patient’s study participation (e.g. scheduled
elective surgery). Pseudoseizureswithin the last year
and uncountable seizures (clusters) or convulsive
status epilepticus within the last 5 years led to
ineligibility. Pregnant or lactating women were not
eligible. Women of childbearing potential had to use
a medically acceptable contraceptive method.
Allergy to LEV and hematological abnormalities
expressed by a neutrophil count < 1800/mm3 and/
or platelets < 100,000/mm3 also led to ineligibility.
All patients or a legally acceptable representa-
tive had to give written informed consent prior to
492 B.J. Steinhoff et al.any study specific procedures. The study was
approved by the local ethical committees.
Study treatment and visits
Treatment
All patients started with an initial dose of
2  500 mg LEV per day, to be taken orally with or
without a meal. If insufficient seizure control was
achieved with that dose, the LEV dose could be
increased in 1000 mg/day steps every 2 weeks up
to 3000 mg daily provided that LEV was well toler-
ated. Betweenweeks 4 and 16 of treatment, the LEV
dose could be modified between 1000 and 3000 mg/
day in increments of 1000 mg at the investigator’s
discretion to achieve maximum benefit regarding
safety and efficacy. A flowchart about the study
course is given in Fig. 1.
In patients with mild renal insufficiency (creati-
nine clearance 50—79 ml/m), the maximal per-
mitted daily dose of LEV was limited to 2000 mg,
in the case of moderate renal insufficiency (creati-
nine clearance 30—49 ml/min) the permitted daily
LEV dose was 500—1500 mg/day. After the final visit
(week 16 or early discontinuation), LEV treatment
could be continued on a prescription basis or the
patient could be progressively withdrawn from LEV
treatment, depending on the decision of the inves-
tigator. In the case of withdrawal, the patient was
recommended to reduce LEV in steps of 1000 mg
every 2 weeks. The accompanying AED therapy had
to remain stable during the study, unless an urgent
medical problem required amodification. The use of
any other concomitant medication had to be
recorded in the CRF including drug name, dose, date
of administration and indication.
Study procedures
Following visit 1 at week 0, patient visits were
scheduled for weeks 2, 4, 10, and 16 and, if applic-
able, 2 weeks following drug withdrawal. At theFigure 1 Schematic timeline.selection visit, written informed consent was
obtained and demographic data collected. A
detailed history (medical, epilepsy, sum of seizures
for the past 3 months for each seizure type, AED and
other concomitant therapy) was recorded. A labora-
tory screening was conducted unless done within 4
weeks prior to V 1 and a pregnancy test was con-
ducted if applicable. The Austrian patients (n = 10)
filled in a QOLIE-10-P (Quality Of Life In Epilepsy).
This is comparable to the Quolie-31-P and includes
items about distress and hierarchy of domains.5 Due
to this methodological inhomogenity among the
three countries, the results are not displayed in this
report. After a physical and neurological examina-
tion, the Daily Record Cards were given and
explained to the patients and LEV was dispensed
in a dosage of 1000 mg/day.
At the visits scheduled for weeks 2, 4, 10, and 16,
seizure count, concomitant medication and adverse
events were documented; the Daily Record Cards
and the study medication were returned and dis-
pensed. Any change in LEV dosage was documented
at each visit. A pregnancy test was repeated at
weeks 4, 10, 16 and at early discontinuation. At
the last visit of the treatment period and the early
discontinuation visit, a physical and neurological
examination was conducted and the investigator
assessed the development of the disease (Global
Evaluation Scale) during the treatment period.
At the last visit of the treatment period, LEV
could be continued on a prescription basis or the
patient could be withdrawn from LEV treatment in
steps of 1000 mg/day every 2 weeks. In the latter
case, the patients were asked to return 2 weeks
following the last dose of LEV for a safety visit,
which included a physical and neurological exam-
ination, the recording of concomitant medications,
adverse events and seizure count.
Efficacy and safety variables
Extent of exposure
In order to define the LEV dosing regimen, a parti-
cular interest was given to dose/duration of expo-
sure and titration schedules.
Safety variables
Safety assessments were made using the reporting
of adverse events.
Efficacy variables
The percentage reduction from historical baseline in
the focal onset (type I) and total (types I + II + III)
seizure frequency per week over the 16-weeks
treatment period.
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Table 1 Baseline demographic and clinical character-
istics of patients enrolled in SKATE.
Parameter Value
Age (years), mean  S.D. 40.7  14.70
Age distribution
N (%) age 16—65 years 165 (92.7%)
N (%) age 65 years 13 (7.3%)
Female/male, n (%) 90/88 (50.6%/49.4%)
Body mass index (kg/m2),
mean  S.D.
25.00  4.65
Duration of epilepsy,
mean  S.D.
24.88  14.98
Age at epilepsy onset,
mean  SD
15.83  13.52
Etiology of epilepsy, n (%)
Unknown 80 (44.9%)
Perinatal/birth events 24 (13.5%)
Congenital malformation 18 (10.1%)
Cerebral infection 12 (6.7%)
Cranial trauma 9 (5.1%)
Cerebral neoplasm 7 (3.9%)
Brain surgery 6 (3.4%)
Cerebrovascular accident 3 (1.7%)The retention rate at 16-weeks, defined as
the number of patients taking LEV at the end of
the 16-weeks treatment period divided by the
number of patients in the intention-to-treat
(ITT) population.
The prospective variables described herein were
analyzed. Seizure-freedom and additional para-
meters derived from the seizure counts were also
analyzed.
Statistical and analytical issues
The analysis was based on the ITT population con-
sisting of all subjects included in the study who took
at least one dose of study medication. The consis-
tency of safety and efficacy results was investigated
by performing summary statistics by country on
adverse events and percentage change from histor-
ical baseline in focal onset seizure frequency per
week over the 16-week treatment period. In this
report, the results of Austria, Germany and Switzer-
land were pooled.Genetic origin 3 (1.7%)
Primary degenerative lesion 2 (1.1%)
Other 24 (13.5%)
Number of AEDs at study entry, n (%)
0 (protocol deviation) 5 (2.8%)
1 81 (45.5%)
2 88 (49.4%)
3 (protocol deviation) 2 (1.1%)Results
Baseline demographic and clinical
characteristics
Of the 178 patients who received at least one dose
of LEV (ITT population), 151 patients (84.8%) com-
pleted the study. The number of males and females
was nearly equivalent, the mean age was 40.7
years (standard deviation 14.7 years, Table 1).
The mean epilepsy duration was 24.9  15.0 years
with a mean onset age of 15.8  13.5 years. At
study entry, 45.5% of the patients were on AED
monotherapy; and 49.4% were taking two AEDs;
1.1% were receiving three or more AEDs and
2.8% were receiving no AEDs. Both were a protocol
deviation since inclusion criteria specified that
only one or two AEDs should be taken at baseline.
Patients without AED treatment had discontinued
previous AEDs due to a lack of efficacy and/or the
presence of adverse events. Most frequently used
AEDs at study entry were carbamazepine (39.9%),
lamotrigine (28.1%), valproic acid (20.8%), oxcar-
bazepine (13.5%) and topiramate (12.4%).
Reasons for early discontinuation were adverse
events (17 patients, 9.6%), lack of efficacy (3
patients, 1.7%), loss to follow-up (2 patients,
1.1%), withdrawal of consent (1 patient, 0.6%),
and other reasons (3 patients, 1.7%). In addition,
the final status of study completion or discontinua-
tion was unknown for one subject.Extent of exposure
Themean duration of LEV treatment in this studywas
108.6  34.5 days; the median duration of exposure
was 113 days (Q25—Q75 = 109.5—120.5). There were
neither marked differences in exposure duration by
gender nor by age. The mean daily dose of LEV was
1847  304 mg (range 250—6000 mg/day); the med-
ian daily dose was 2000 mg (Q25—Q75 = 1000—
3000 mg). Again, no significant differences in LEV
dose by gender or by age could be detected.
Safety
Altogether 108 patients (60.7%) of the ITT population
experienced at least one adverse event during the
treatment period, 8 patients (4.5%) suffered from a
serious adverse event (SAE). Serious adverse events
with a possible relationship to LEV treatment were
reported from 4 patients (2.2%) including a series
of seizures with hospitalization, an acute episode
of agitated depression with somatoform symptoms,
tremor and psychosis. Except for the series of
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Table 2 Treatment-emergent adverse events experienced overall by5% of the 178 patients enrolled, broken down
by intensity or relationship to LEV treatment.
Adverse event Total N (%) Intensity Relationship to LEV treatment
Mild N Moderate N Severe N Not related N Related N (%)
Asthenia 29 (16.3%) 18 9 2 3 26 (14.6%)
Dizziness 20 (11.2%) 9 11 0 4 16 (9.0%)
Headache 15 (8.4%) 3 7 5 5 10 (5.6%)
Nausea 12 (6.7%) 6 4 2 2 10 (5.6%)
Somnolence 12 (6.7%) 6 4 2 1 11 (6.2%)
Hostility 9 (5.1%) 7 2 0 0 9 (5.1%)seizures, these events led to discontinuation of LEV
treatment. One SUDEP (SuddenUnexplainedDeath in
EPilepsy) occurred in the study whichwas assessed as
unlikely tobe related toLEV treatment. Likewise, the
three remaining SAEs were assessed as unlikely to be
related to LEV treatment: humerus fracture, status
epilepticus and eczema.
Treatment-emergent adverse events that
occurred in 5% of patients were asthenia (29
patients, 16.3%), dizziness (20, 11.2%), headache
(15, 8.4%), nausea and somnolence (12, 6.7% each)
and hostility (9, 5.1%), most of these events were of
mild or moderate intensity (Table 2).
Other adverse events related to the nervous
system were rare: tremor (7 patients, 3.9%), con-
vulsion (5, 2.8%), insomnia (4, 2.2%), ataxia, depres-
sion, abnormal thinking and nervousness (3, 1.7%
each). Altogether, 19 patients (10.7%) experienced
adverse events with severe intensity, reported from
more than one patient were headache (5 patients,
2.8%), vomiting (3 patients, 1.7%), and asthenia,
somnolence, malaise and nausea with 2 patients
(1.1%) each. Other severe adverse events only
occurred in single cases. Adverse events led to study
drug discontinuation in 16 patients (9.0%), most
frequent reasons were nausea, vomiting, asthenia,
headache and tremor.
Efficacy
The add-on treatment of LEV to a stable AED
medication led to a median reduction of seizureTable 3 Comparison of baseline demographic and
epilepsy characteristics between phase III studies
and SKATE.
Parameter Phase III SKATE
Mean age (years  S.D.) 37.4  11.3 40.7  14.7
Median epilepsy
duration (years)
22 23.7
Median age at epilepsy
onset (years)
12 12.5
Median baseline seizure
frequency per month
9 4frequency over the 16-weeks treatment period for
focal seizures of 47.6% (Q25—Q75 = 4.7—87.6), for
total seizures the reduction was 46.5% (Q25—
Q75 = 1.7—84.1, Table 3).
The 50% responder rate, defined as the percen-
tage of patients experiencing a reduction in seizure
frequency of 50% or more over the treatment period
was 46.6% for focal and 45.1% for all seizures.
Seizure freedom over the treatment period was
achieved in 16.7% of the patients with focal seizures
and in 16.6% of the patients with total seizures.
The retention rate (number of patients taking
LEVat the end of the 16-week treatment period) was
84.8%.Discussion
Compared with the pivotal studies conducted to get
approval for LEV, the patient population of the
SKATE study more closely reflects the patients seen
in daily clinical practice. Thus, the pooled analysis
of the patients enrolled in SKATE in Austria, Ger-
many and Switzerland is able to provide safety and
efficacy data which is a better reflection of the usual
antiepileptic therapy. Nevertheless, all patients
enrolled in SKATE had uncontrolled epilepsy and
received one or two AEDs at baseline. AED mono-
therapy was taken by 45.5% of the patients at base-
line, 49.4% were taking two AEDs; 1.1% were
receiving three or more AEDs and 2.8% were receiv-
ing no AED. The rate of 84.8% of patients completing
the trial is exceptionally high for a phase IV trail and
similar to the rate of 85% seen in phase III controlled
clinical studies.2,3,14
The results of SKATE in Austria, Germany and
Switzerland match favourably with those from
phase III controlled clinical studies2,3,14 as well as
with findings from another phase IV study with a
similar design to SKATE, the KEEPER (Keppra Epi-
lepsy Evaluation of the Patient timE to Response)
trial.11 The main difference between SKATE and the
phase III studies was the randomized assignment of
the phase III patients to a fixed dose of LEV after a
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Table 4 Reduction in seizure frequency over the treatment period compared to baseline.
Seizure type Baseline seizure frequency/week Reduction from baseline (%)
N Median Q25—Q75 N Median Q25—Q75
Partial (type I) 177 0.93 0.5—1.9 168 47.6 4.7—87.6
Total (types I + II + III) 178 0.93 0.6—2.0 174 46.5 1.7—84.1titration period. In the KEEPER study, the dose was
increased by 500 mg b.i.d. every 2 weeks up to
1500 mg b.i.d. unless seizure freedom was achieved
before. The dose was then to remain stable through-
out the treatment period, whereas in SKATE the dose
could be adjusted throughout the study according to
efficacy and safety variables to achieve maximum
benefit for the patients. Therefore, it could be
expected that theefficacy and safety of LEVobserved
in the SKATE study might be slightly better compared
with the phase III and the KEEPER study and thus
compensate the theoretical drawbacks caused by the
fact that more traditional European epilepsy centres
participated in SKATE with a study population that
might have been more refractory.
The efficacy criteria 50% seizure reduction and
seizure freedom rates for focal onset seizures in
SKATE are commonly used in studies evaluating AEDs
in patient populations with a wide range of variation
as well as a non-normal distribution of epileptic
seizures.1,6 These efficacy parameters were also
evaluated in the pivotal phase III clinical studies,
which facilitates the comparison of LEV efficacy in
the relatively homogeneous patient populations
recruited in the phase III studies versus the more
heterogeneous patient populations recruited for the
SKATE study.
The demographic and baseline epilepsy charac-
teristics of the patients in the phase III clinical trials
and SKATE were similar (Table 4), except for the
median baseline seizure frequency which was with
9.0 per month in the phase III studies higher than in
SKATE with four per month.2,3,14
The 50% responder rate in SKATE confirms the
results found in the phase III trials: 46.6% for focal
onset seizures versus 28.5% for1000 mgLEV, 34.3% for
2000 mg LEV and 41.3% for the 3000 mg LEV treat-
ment group in the phase III studies. As mentioned
before, the higher 50% responder rate in SKATEcanbe
explained by the flexible dose that could be adapted
to the patient’s needs. The seizure freedom rates
under LEV treatment in patients with focal-onset
seizures support this explanation: 16.7% in SKATE,
compared to 4.7% for 1000 mg, 6.3% for 2000 mg and
8.6% for 3000 mg LEV daily in the phase III studies.
Thus, results from SKATE in Austria, Germany and
Switzerland reported here indicate that LEV is even
more efficient than shown in phase III trials when
used in a setting more closely reflecting daily prac-tice with regard to patient population and treat-
ment regimen.
Comparing the results of SKATE with another
community-based LEV trial, the KEEPER study, the
baseline characteristics of the patient populations
were similar: mean age 42.2  14.5 years in KEEPER
versus 40.7  14.7 years in SKATE, median epilepsy
duration 18.4 versus 23.7 years and median age at
epilepsy onset 18.3 versus 12.5 years, median base-
line seizure frequency per month 3.6 (KEEPER) ver-
sus 4 in SKATE.11 Thus, the patients in KEEPER were
slightly older but had a shorter epilepsy duration
with later onset age. The 50% responder rate for
focal seizure patients in the KEEPER population was
57.9% versus 46.6% in SKATE; the seizure freedom
rate was 20.0% in KEEPER versus 16.7% in SKATE.
These slightly higher rates in KEEPER may result
from the high percentage of patients treated in
traditional European epilepsy centers who usually
reflect a population of the most difficult-to-treat
epilepsy patients. On the other hand, considering
this possible selection drawback, the SKATE results
emphasize the favorable efficacy profile of LEV.
SKATE also supports the safety data evaluated in
the phase III studies with an equal rate of 9% of the
patients discontinued permanently from the study
due to an adverse event.2,3,14 The adverse event
profile was comparable in the phase III trials and
SKATE: most frequent were asthenia 16.3% (SKATE)
versus 14.1% (phase III), dizziness (11.2% versus
9.2%), headache (8.4% versus 13.1%) and somnolence
(6.7% versus 14.9%). The frequency of these adverse
events was similar in the SKATE interim analysis of all
participating centers in the countries having entirely
finished the study: asthenia 19.2%, dizziness 9.7%,
headache 11.2% and somnolence 16.7%.
In conclusion, the results of the SKATE study
centres in Austria, Germany and Switzerland
support the efficacy and safety results of the
phase III trials with an even more pronounced
efficacy in a setting better reflecting the patients
and treatment options appearing in daily clinical
practice compared to the settings in the phase III
studies.Acknowledgement
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